<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808871</url>
  </required_header>
  <id_info>
    <org_study_id>TRAIL1</org_study_id>
    <nct_id>NCT02808871</nct_id>
  </id_info>
  <brief_title>Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)</brief_title>
  <official_title>Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivan O. Rosas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403
      mg/day for the treatment of RA-associated interstitial lung disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, randomized, double blind, placebo controlled trial of pirfenidone for the
      treatment of RA associated interstitial lung disease. Approximately 270 subjects will be
      randomized to receive Pirfenidone 2403 mg per day or placebo in a 1:1 ratio. The primary
      outcome of this study is to assess the efficacy of pirfenidone 2403 mg/day versus placebo in
      patients with RA associated interstitial lung disease, as defined by progression free
      survival over the 52 weeks of treatment. Patients will receive blinded study treatment from
      the time of randomization until the Week 52 Visit.

      Eligible patients aged 18 to 85 years must meet 2010 ACR/EULAR criteria for RA (Aletaha,
      Neogi et al. 2010) as well as RA-associated ILD, as determined by imaging and, when
      available, lung biopsy. Patients will be required to have a % predicted FVC ≥40 and %
      predicted DLCO ≥30 at screening.

      The dose of study treatment will be titrated over 14 days. Patients will receive a telephone
      assessment at Weeks 1 and 2, and visit the clinic at Weeks 4, 8, 13, 19, 26, 39, and 52.
      Subjects will have a follow up phone call 28 days after completion of the study drug.
      Patients should complete a compliance diary between visits. If patients discontinue study
      treatment for any reason before the end of the study, they should continue with all scheduled
      study procedures through Week 52. If subjects are unable to complete the study visits as
      scheduled, all efforts should be made to complete an early termination visit.

      The primary outcome variable of this study will be progression free survival, defined as
      progression free from decline in FVC of 10% or greater during the 52 week study period.

      More information can be found at www.ralung.org.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of the composite endpoint</measure>
    <time_frame>52 weeks</time_frame>
    <description>Incidence of the composite endpoint of decline in percent predicted FVC of 10% or greater or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of the composite endpoint</measure>
    <time_frame>52 weeks</time_frame>
    <description>Incidence of the composite endpoint of decline in percent predicted forced vital capacity (FVC) of 10% or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of progressive disease</measure>
    <time_frame>52 weeks</time_frame>
    <description>Frequency of progressive disease as defined by OMERACT: FVC% relative decline of &gt;=10% or FVC% change in &gt;=5&lt; 10% and &gt;=15% diffusing capacity (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% FVC change stratified by background therapy</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% FVC change stratified by Usual Interstitial Pneumonitis (UIP) vs. non-UIP pattern on HRCT</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean slope of FVC</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to decline of 10% or greater in percent predicted FVC or death</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute exacerbation of interstitial lung disease (ILD)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause hospitalization</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for respiratory cause</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute exacerbation of ILD</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of respiratory exacerbations requiring hospitalizations</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse Events (AEs)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent serious adverse events (SAEs)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent/treatment-related AEs</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent/treatment-related SAEs</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs leading to early discontinuation of study treatment</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent death or transplant</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent RA-ILD-related mortality</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 52 in dyspnea, as measured by the University of California at San Diego Shortness-of-Breath Questionnaire (UCSD SOBQ) score</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 52 on St. George's Respiratory Questionnaire</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Disease Activity Score (DAS)/Routine assessment of patient index data (RAPID)3 score (RA disease activity scores)</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Joint counts</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>erythrocyte sedimentation rate (ESR)/c-reactive protein (CRP)</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Candidate biomarker expression in the peripheral blood of patients with RA-ILD over the 52 weeks of treatment and the study follow-up period</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Extent and severity of fibrotic lung involvement, as measured by changes in Chest CT scans evaluated by quantitative functional imaging</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Rheumatoid Arthritis Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pirfenidone 2403 mg/d for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone three times daily (2403 mg) for 52 weeks</description>
    <arm_group_label>Pirfenidone</arm_group_label>
    <other_name>Esbriet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo three times daily for 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of Interstitial Lung Disease:

          1. Age 18 through 85 years, inclusive, at screening

          2. Diagnosis of RA according to revised 2010 ACR/EULAR criteria

          3. Diagnosis of ILD

               1. Supported by clinically indicated HRCT, and when available surgical lung biopsy
                  (SLB).

               2. Presence of reticular abnormality affecting more than 10% of the lung parenchyma,
                  with or without traction bronchiectasis or honeycombing, on HRCT

          4. No features supporting an alternative diagnosis on transbronchial biopsy,
             bronchoalveolar lavage (BAL), or SLB, if performed

          5. Attainment of the following centralized spirometry criteria (based on local spirometry
             on standardized equipment and centralized quality controlled):

               1. % predicted FVC ≥ 40% at Screening

               2. Change in pre- and post-bronchodilator FVC (measured in liters) between Screening
                  (Visit 1) and Visit 2 must be a &lt;10% relative difference, calculated as shown
                  below:

                  Screen FVC (L) - Day 1 FVC (L) × 100% Screen FVC (L)

               3. %predicted DLCO ≥ 30% at Screening

             Informed Consent and Protocol Adherence:

          6. Able to understand and sign a written informed consent form

          7. Pregnancy or lactation. For women of childbearing potential: agreement to remain
             abstinent (refrain from heterosexual intercourse) or use two adequate methods of
             contraception, including at least one method with a failure rate of &lt;1% per year,
             during the 52 week treatment period and for at least 118 days after the last dose of
             study drug.

          8. For men who are not surgically sterile: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive measures, and agreement to refrain from
             donating sperm.

        Exclusion Criteria:

        Disease-Related Exclusions:

          1. Not a suitable candidate for enrollment or unlikely to comply with the requirements of
             this study, in the opinion of the investigator

          2. Cigarette smoking within 3 months of Screening or unwilling to avoid tobacco products
             throughout the study

          3. History of clinically significant environmental exposure known to cause pulmonary
             fibrosis (PF), including but not limited to drugs (such as amiodarone), asbestos,
             beryllium, radiation, and domestic birds

          4. Concurrent presence of the following conditions:

               1. other interstitial lung disease, related to but not limited to radiation, drug
                  toxicity, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans
                  organizing pneumonia,

               2. Medical history including Human Immunodeficiency Virus (HIV),

               3. Medical history of viral hepatitis (positive Hep A antibody in the absence of
                  elevated liver enzymes is not an exclusion)

          5. Concurrent presence of other pleuropulmonary manifestations of RA, including but not
             limited to rheumatoid nodular disease of the lung, pleuritis/pleural thickening, and
             obliterative bronchiolitis

          6. Post-bronchodilator FEV1/FVC &lt; 0.7

          7. Presence of pleural effusion occupying more than 20% of the hemithorax

          8. Clinical diagnosis of a second connective tissue disease or overlap syndrome
             (including but not limited to scleroderma, sjogren's,polymyositis/dermatomyositis,
             systemic lupus erythematosus, but excluding Raynaud's phenomena)

          9. Coexistent clinically significant COPD/emphysema or asthma in the opinion of the site
             principle investigator

             Medical Exclusions:

         10. Clinical evidence of active infection, including but not limited to bronchitis,
             pneumonia, sinusitis, urinary tract infection, or cellulitis. The infection should be
             resolved per PI assessment prior to enrollment. Any use of antibiotics must be
             completed 4 2weeks prior to the screening visit. Note that prophylactic antibiotics
             are not contraindicated or exclusionary.

         11. Any history of malignancy diagnosed within 5 years of screening, other than basal cell
             carcinoma of the skin, squamous cell carcinoma of the skin, or low grade cervical
             carcinoma in situ.

         12. History of LFT abnormalities as outlined below, or imaging, laboratory or other
             clinical information suggesting liver dysfunction, advanced liver disease or
             cirrhosis. Evidence of hepatic impairment that in the opinion of the investigator
             could interfere with drug metabolism or increase the risk of the known hepatotoxicity
             of study drug.

             Any of the following liver function abnormalities:

               1. Total bilirubin above the upper limit of normal (ULN), excluding patients with
                  Gilbert's syndrome;

               2. Aspartate or alanine aminotransferase (AST/SGOT or AST/SGPT) &gt; 3 X ULN;

               3. Alkaline phosphatase &gt; 2.5 X ULN.

         13. History of end-stage renal disease requiring dialysis

         14. History of unstable or deteriorating cardiac disease, or unstable cardiac arrhythmia
             or arrhythmia requiring modification of drug therapy, myocardial infarction within the
             previous year, heart failure requiring hospitalization.

         15. Any condition that, in the opinion of the investigator, might be significantly
             exacerbated by the known side effects associated with the administration of
             pirfenidone

         16. History of alcohol or substance abuse in the past 2 years, at the time of screening

         17. Family or personal history of long QT syndrome.

             Laboratory Exclusions:

         18. Any of the following test criteria above specified limits:

               1. Estimated glomerular filtration rate &lt; 57

               2. Electrocardiogram (ECG) with a QTc interval &gt;500 msec at Screening

             Medication Exclusions:

         19. Prior use of pirfenidone or known hypersensitivity to any of the components of study
             treatment

         20. Use of any of the following therapies within 28 days before Screening and during
             participation in the study:

               1. Investigational therapy, defined as any drug that has not been approved for
                  marketing for any indication in the country of the participating site

               2. Potent inhibitors of CYP1A2 (e.g. fluvoxamine, enoxacin)

               3. Sildenafil (daily use). Note: intermittent use for erectile dysfunction is
                  allowed

         21. Introduction and/or modification of dose of corticosteroids or any cytotoxic,
             immunosuppressive, or cytokine modulating or receptor antagonist agent for the
             management of pulmonary manifestations of RA, within 3 months of screening, is an
             exclusion criterion, for enrollment, with the exception of dose modification of
             systemic corticosteroids that are maintained at or below 20 mg prednisone daily or the
             equivalent.

         22. Any use of an approved anti-fibrotic medication.

        However, introduction and/or modification of dose of corticosteroids or any cytotoxic,
        immunosuppressive, or cytokine modulating or receptor antagonist agent for the management
        of extrapulmonary manifestations of RA is not an exclusion criterion for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan O. Rosas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivan Rosas, M.D.</last_name>
    <phone>617-510-9910</phone>
    <email>ivan.rosas@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Site at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joao DeAndrade, MD</last_name>
      <phone>205-934-4328</phone>
      <email>jdeandrade@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vickie Desarro</last_name>
      <phone>205-934-5573</phone>
      <email>vdesarro@uabmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey J. Swigris, D.O., M.S.</last_name>
      <phone>303-875-7541</phone>
      <email>swigrisj@njhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlyn Fier</last_name>
      <phone>303-398-1220</phone>
      <email>Fierk@njhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Glassberg, MD</last_name>
      <phone>305-243-3728</phone>
      <email>ESimonet@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bethly Aubourg</last_name>
      <phone>305-243-3728</phone>
      <email>baubourg@med.miami.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph A. Lasky, M.D.</last_name>
      <phone>504-988-8600</phone>
      <email>jlasky@tulane.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine Glynn</last_name>
      <phone>504-988-0743</phone>
      <email>cglynn1@tulane.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>John Hopkins Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karthik Suresh, M.D.</last_name>
      <phone>410-550-2062</phone>
      <email>ksuresh2@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leena Matthew</last_name>
      <phone>410-550-2062</phone>
      <email>lmathew@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Dellaripa, MD</last_name>
      <phone>617-732-5548</phone>
      <email>pdellaripa@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Poli De Frias Sergio</last_name>
      <phone>617-525-7370</phone>
      <email>SPOLI@bwh.harvard.ed</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin R. Flaherty, M.D.</last_name>
      <phone>734-647-9342</phone>
      <email>flaherty@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Candace Flaherty</last_name>
      <phone>734-936-8301</phone>
      <email>cflah@umich.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Limper, M.D.</last_name>
      <phone>507-284-4162</phone>
      <email>limper.andrew@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kaner, MD</last_name>
      <phone>646-962-2333</phone>
      <email>rkaner@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alicia Morris</last_name>
      <phone>646-962-2741</phone>
      <email>ajm2017@med.cornell.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Highland, MD</last_name>
      <phone>216-445-0574</phone>
      <email>highlak@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Ron Wehrmann</last_name>
      <phone>216-445-0574</phone>
      <email>wehrmar@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa H. Lancaster, M.D.</last_name>
      <phone>615-322-5879</phone>
      <email>lisa.lancaster@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eric Smith</last_name>
      <phone>615-343-7068</phone>
      <email>eric.b.smith@vumc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Care</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Scholand, M.D</last_name>
      <phone>801-581-7806</phone>
      <email>scholand@genetics.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Martinez</last_name>
      <phone>801-213-2650</phone>
      <email>Joseph.martinez@utah.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganesh Raghu, MD</last_name>
      <phone>206-598-4967</phone>
      <email>graghu@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Reba Bissell</last_name>
      <phone>206-616-8723</phone>
      <email>blissr@uw.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Brisbane</state>
        <zip>QLD 4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chambers, MD</last_name>
      <phone>+61 7 3139 4000</phone>
      <email>Daniel.Chambers@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Debra Enever</last_name>
      <email>enever@health.qld.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>Sydney</state>
        <zip>NSW 2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Troy, MD</last_name>
      <phone>9515 5006</phone>
      <email>Troy@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Cleary</last_name>
      <email>Shannon.Cleary@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Melbourne Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Glasspole, MD</last_name>
      <phone>61 3 9076 6963</phone>
      <email>i.glaspole@alfred.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Karen Symons</last_name>
      <email>K.Symons@alfred.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Calgary Cummings School of Medicine</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene D. Fell, MD</last_name>
      <phone>403-956-3826</phone>
      <email>Charlene.Fell@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mark Hyman</last_name>
      <phone>403-956-3826</phone>
      <email>Mark.Hyman@albertahealthservices.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital - Providence Health Care</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Ryerson, MD</last_name>
      <phone>604-682-2344</phone>
      <phone_ext>62489</phone_ext>
      <email>Chris.Ryerson@hli.ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia MacDonald</last_name>
      <phone>604-806-8117</phone>
      <email>cmacdonald3@providencehealth.bc.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Cox, MD</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35003</phone_ext>
      <email>coxp@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Goodman</last_name>
      <phone>905-521-6130</phone>
      <email>sgoodwin@stjosham.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shane Shapera, MD</last_name>
      <phone>416-581-8586</phone>
      <email>Shane.Shapera@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust Headquarters, Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huzaifa Adamali, MD</last_name>
      <phone>07530 426423</phone>
      <email>Huzaifa.Adamali@nbt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Anna Morley</last_name>
      <email>Anna.Morley@nbt.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Parfrey, MD</last_name>
      <phone>01480 364521</phone>
      <email>helen.parfrey@papworth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kane Dorey</last_name>
      <email>kanedorey@nhs.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Foundation</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gibbons, MD</last_name>
      <phone>01392 411 611</phone>
      <email>Michael.gibbons2@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Sinead Kelly</last_name>
      <email>sineadkelly@nhs.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Beirne, MD</last_name>
      <phone>0113 206 5113</phone>
      <email>p.beirne@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Sumit Lahiri</last_name>
      <email>sumit.lahiri@nhs.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Foundation Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bibek Goopta, MD</last_name>
      <phone>0116 258 3325</phone>
      <email>bibek.gooptu@uhl-tr.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Harris</last_name>
      <email>victoria.harris@uhl-tr.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Spencer, MD</last_name>
      <phone>0151 529 2077</phone>
      <email>Lisa.spencer@aintree.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jo Brown</last_name>
      <email>jo.brown@Aintree.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Brompton and Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toby Maher, MD</last_name>
      <phone>02073528121</phone>
      <email>T.Maher@rbht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Sara Shaheen</last_name>
      <email>S.Shaheen@rbht.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust (South) Wythenshawe Hospita</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazia Chaudhuri, MD</last_name>
      <phone>0161 998 7070</phone>
      <email>nazia.chaudhuri@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Bindhu Xavier</last_name>
      <email>bindhu.xavier@uhsm.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Forrest, MD</last_name>
      <phone>0191 233 6161</phone>
      <email>ian.forrest@nuth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Alison Sutherland</last_name>
      <email>Alison.sutherland@ncl.ac.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Wilson, MD</last_name>
      <phone>01603 286286</phone>
      <email>a.m.wilson@uea.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Madhu Sarangi</last_name>
      <email>MADHUSMITA.SARANGI@nnuh.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Hoyles, MD</last_name>
      <phone>0300 304 7777</phone>
      <email>Hoyles@ouh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Tomas Bailey</last_name>
      <email>Tomas.Bailey@ouh.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southhampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Fletcher, MD</last_name>
      <phone>023 8077 7222</phone>
      <email>Sophie.fletcher@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Rachael Collings</last_name>
      <email>Rachael.collings@uhs.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Ivan O. Rosas</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>TRAIL1</keyword>
  <keyword>TRAIL</keyword>
  <keyword>Pirfenidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

